An Open-label, Randomized, Multi-center, Parallel Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

NCT02227875 Phase 3 COMPLETED Results posted

To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (both administered in combination with other anti-diabetic drugs) based on the change in HbA1c from baseline to 24 weeks

Details

Lead sponsor	Mylan Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	560
Start date	2014-08
Completion	2015-12

Conditions

• Type 2 Diabetes

Interventions

• Mylan's insulin glargine
• Lantus®

Primary outcomes

• Change in HbA1c From Baseline to 24 Weeks — 24 weeks

Countries

United States, Jordan, Slovakia, South Africa, South Korea, Taiwan